Biological markers of amyloid beta-related mechanisms in Alzheimer's disease.

Hdl Handle:
http://hdl.handle.net/10147/207766
Title:
Biological markers of amyloid beta-related mechanisms in Alzheimer's disease.
Authors:
Hampel, Harald; Shen, Yong; Walsh, Dominic M; Aisen, Paul; Shaw, Les M; Zetterberg, Henrik; Trojanowski, John Q; Blennow, Kaj
Affiliation:
Discipline of Psychiatry, School of Medicine and Trinity College Institute of, Neuroscience (TCIN), Laboratory of Neuroimaging and Biomarker Research, Trinity, College Dublin, Trinity Centre for Health Sciences, The Adelaide and Meath, Hospital Incorporating The National Children's Hospital (AMiNCH), Dublin,, Ireland; Department of Psychiatry, Alzheimer Memorial Center, Ludwig Maximilian, University, Munich, Germany.
Citation:
Exp Neurol. 2010 Jun;223(2):334-46. Epub 2009 Oct 6.
Journal:
Experimental neurology
Issue Date:
1-Feb-2012
URI:
http://hdl.handle.net/10147/207766
DOI:
10.1016/j.expneurol.2009.09.024
PubMed ID:
19815015
Abstract:
Recent research progress has given detailed knowledge on the molecular pathogenesis of Alzheimer's disease (AD), which has been translated into an intense, ongoing development of disease-modifying treatments. Most new drug candidates are targeted on inhibiting amyloid beta (Abeta) production and aggregation. In drug development, it is important to co-develop biomarkers for Abeta-related mechanisms to enable early diagnosis and patient stratification in clinical trials, and to serve as tools to identify and monitor the biochemical effect of the drug directly in patients. Biomarkers are also requested by regulatory authorities to serve as safety measurements. Molecular aberrations in the AD brain are reflected in the cerebrospinal fluid (CSF). Core CSF biomarkers include Abeta isoforms (Abeta40/Abeta42), soluble APP isoforms, Abeta oligomers and beta-site APP-cleaving enzyme 1 (BACE1). This article reviews recent research advances on core candidate CSF and plasma Abeta-related biomarkers, and gives a conceptual review on how to implement biomarkers in clinical trials in AD.
Language:
eng
MeSH:
Alzheimer Disease/drug therapy/*metabolism/*pathology; Amyloid beta-Peptides/*metabolism; Biological Markers/*metabolism; Brain/metabolism/pathology; Clinical Trials as Topic/methods; Humans
ISSN:
1090-2430 (Electronic); 0014-4886 (Linking)

Full metadata record

DC FieldValue Language
dc.contributor.authorHampel, Haralden_GB
dc.contributor.authorShen, Yongen_GB
dc.contributor.authorWalsh, Dominic Men_GB
dc.contributor.authorAisen, Paulen_GB
dc.contributor.authorShaw, Les Men_GB
dc.contributor.authorZetterberg, Henriken_GB
dc.contributor.authorTrojanowski, John Qen_GB
dc.contributor.authorBlennow, Kajen_GB
dc.date.accessioned2012-02-01T10:47:53Z-
dc.date.available2012-02-01T10:47:53Z-
dc.date.issued2012-02-01T10:47:53Z-
dc.identifier.citationExp Neurol. 2010 Jun;223(2):334-46. Epub 2009 Oct 6.en_GB
dc.identifier.issn1090-2430 (Electronic)en_GB
dc.identifier.issn0014-4886 (Linking)en_GB
dc.identifier.pmid19815015en_GB
dc.identifier.doi10.1016/j.expneurol.2009.09.024en_GB
dc.identifier.urihttp://hdl.handle.net/10147/207766-
dc.description.abstractRecent research progress has given detailed knowledge on the molecular pathogenesis of Alzheimer's disease (AD), which has been translated into an intense, ongoing development of disease-modifying treatments. Most new drug candidates are targeted on inhibiting amyloid beta (Abeta) production and aggregation. In drug development, it is important to co-develop biomarkers for Abeta-related mechanisms to enable early diagnosis and patient stratification in clinical trials, and to serve as tools to identify and monitor the biochemical effect of the drug directly in patients. Biomarkers are also requested by regulatory authorities to serve as safety measurements. Molecular aberrations in the AD brain are reflected in the cerebrospinal fluid (CSF). Core CSF biomarkers include Abeta isoforms (Abeta40/Abeta42), soluble APP isoforms, Abeta oligomers and beta-site APP-cleaving enzyme 1 (BACE1). This article reviews recent research advances on core candidate CSF and plasma Abeta-related biomarkers, and gives a conceptual review on how to implement biomarkers in clinical trials in AD.en_GB
dc.language.isoengen_GB
dc.subject.meshAlzheimer Disease/drug therapy/*metabolism/*pathologyen_GB
dc.subject.meshAmyloid beta-Peptides/*metabolismen_GB
dc.subject.meshBiological Markers/*metabolismen_GB
dc.subject.meshBrain/metabolism/pathologyen_GB
dc.subject.meshClinical Trials as Topic/methodsen_GB
dc.subject.meshHumansen_GB
dc.titleBiological markers of amyloid beta-related mechanisms in Alzheimer's disease.en_GB
dc.contributor.departmentDiscipline of Psychiatry, School of Medicine and Trinity College Institute of, Neuroscience (TCIN), Laboratory of Neuroimaging and Biomarker Research, Trinity, College Dublin, Trinity Centre for Health Sciences, The Adelaide and Meath, Hospital Incorporating The National Children's Hospital (AMiNCH), Dublin,, Ireland; Department of Psychiatry, Alzheimer Memorial Center, Ludwig Maximilian, University, Munich, Germany.en_GB
dc.identifier.journalExperimental neurologyen_GB
dc.description.provinceLeinster-

Related articles on PubMed

All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.